Related Experiment Videos
Bromo-DMA: the Australasian hallucinogen?
The Australian and New Zealand Journal of Psychiatry
|September 1, 1983
Summary
Bromo-DMA, a novel hallucinogen, is responsible for most toxic states from hallucinogen abuse in Australasia, not LSD. Two intoxication cases were successfully treated with haloperidol, with full recovery within 24 hours.
Area of Science:
- Toxicology
- Pharmacology
- Neuroscience
Background:
- Hallucinogen abuse poses significant public health challenges.
- Lysergic acid diethylamide (LSD) is commonly perceived as the primary hallucinogen involved in toxic states.
- Understanding the prevalence of different hallucinogens is crucial for effective treatment and prevention.
Observation:
- Police seizures of hallucinogens may indicate ingestion frequency in Australasia.
- Two cases of intoxication involving a new hallucinogen, Bromo-DMA, were observed.
- Patients presented with acute toxic states attributed to hallucinogen abuse.
Findings:
- Bromo-DMA appears to be more frequently implicated in toxic states than LSD in Australasia.
- Both reported cases of Bromo-DMA intoxication showed complete recovery.
- Haloperidol treatment was effective in managing the acute symptoms of Bromo-DMA intoxication.
Implications:
- Clinical and forensic toxicology practices should consider Bromo-DMA as a significant cause of hallucinogen-related emergencies.
- Public health messaging regarding hallucinogen risks may need re-evaluation.
- Further research into the pharmacodynamics and epidemiology of Bromo-DMA is warranted.